Why the study?
Myocardial bridging can cause significant cardiac symptoms, ischemia, arrhythmia, and sudden cardiac death, requiring effective diagnostic and treatment approaches.
This review highlights that myocardial bridging is a treatable condition requiring a comprehensive diagnostic and therapeutic approach to mitigate risks of ischemia, arrhythmia, and sudden cardiac death.
May support combined management strategies for myocardial bridging; leaves open need for prospective trials to confirm outcomes.
Myocardial bridging (MB) is a congenital coronary artery anomaly involving an overlying myocardium's partial or complete encasement of a coronary artery segment. The obstruction can lead to significant cardiac symptoms, resulting in myocardial ischemia, arrhythmia, and sudden cardiac death. Several approaches, including invasive and non-invasive methods, have been proposed to diagnose and manage MB. Invasive modalities, such as intravascular ultrasound (IVUS) and coronary angiography, offer high specificity and sensitivity. In contrast, non-invasive methods like Doppler ultrasound, multislice computed tomography (MSCT), and magnetic resonance imaging (MRI) are advantageous due to their non-invasive nature, high sensitivity and specificity, and cost-effectiveness. Treatment options for MB mainly focus on relieving symptoms and preventing adverse outcomes. The use of pharmacological agents and surgical and percutaneous interventions has been documented in numerous studies. Studies conclude that MB is a treatable cardiac anomaly, and a combined approach of diagnosis, treatment, and follow-up is necessary to reduce the morbidity and mortality associated with this condition.
No takes yet. Share an insight, caveat, or question.
Evbayekha et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: